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Abstract: Chronic inflammation plays a key tumor-promoting role in lung cancer. Our 
previous studies in mice demonstrated that neutrophils are critical mediators of tumor 
promotion in methylcholanthrene (MCA)-initiated, butylated hydroxytoluene (BHT)-promoted 
lung carcinogenesis. In the present study we investigated the role of neutrophil 
myeloperoxidase (MPO) activity in this inflammation promoted model. Increased levels of 
MPO protein and activity were present in the lungs of mice administered BHT. Treatment 
of mice with N-acetyl lysyltyrosylcysteine amide (KYC), a novel tripeptide inhibitor of 
MPO, during the inflammatory stage reduced tumor burden. In a separate tumor model, 
KYC treatment of a Lewis Lung Carcinoma (LLC) tumor graft in mice had no effect on 
tumor growth, however, mice genetically deficient in MPO had significantly reduced LLC 
tumor growth. Our observations suggest that MPO catalytic activity is critical during the 
early stages of tumor development. However, during the later stages of tumor progression, 
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MPO expression independent of catalytic activity appears to be required. Our studies 
advocate for the use of MPO inhibitors in a lung cancer prevention setting.  
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1. Introduction 
Lung cancer remains the major cause of cancer-related death in the Western World [1–5]. While 
surgical resection is effective for those with early stage disease, the majority of patients present with 
advanced malignancies requiring systemic and cytotoxic treatments such as chemotherapy, which have 
limited efficacy. Consequently, chemoprevention by medicines tailored to individuals at high-risk for 
lung cancer (e.g., underlying inflammatory disease, heavy smokers, familial history) remains a 
promising disease control alternative. Identification of molecular targets of prevention and evaluation 
of non-toxic agents in pre-clinical animal models of lung cancer is a necessary prerequisite to 
chemoprevention in humans. 
As early as the 19th century it was observed that chronic inflammation in certain tissues predisposes 
one to cancer [6–9]. Prolonged inflammation can induce DNA damage due to increased exposure to 
oxidative stress [10]. To model the role of lung inflammation in tumorigenesis, a 2-stage approach is 
often used. This involves single administration of the tobacco-related carcinogen 3-methylcholanthrene 
(MCA) to initiate tumorigenesis, followed by multiple administrations of the lung injury agent 
butylated hydroxytoluene (BHT) to promote tumorigenesis. BHT is non-carcinogenic and causes 
epithelial necrosis, resulting in compensatory proliferation of airway epithelial cells and significant 
leukocyte infiltration into the lung [11–16]. The MCA/BHT model is a widely accepted tumor 
promoter and model of lung injury [11,15,17,18]. Using cell depletion studies, we previously reported 
that neutrophils (and not T lymphocytes) are critical mediators of lung tumor promotion by BHT [19]. 
Others have demonstrated that inhibition of IL8 receptor-dependent neutrophil recruitment impedes 
tumor formation in inflammation-driven cancer models of the colon and skin [20]. These observations 
mirror the association of lung neutrophilia with increased risk of lung cancer as seen in chronic 
obstructive pulmonary disorder (COPD) [21–25]. In humans, elevated numbers of neutrophils in 
bronchoalveolar lavage fluid (BALF), blood, or tumor tissue from lung cancer patients is prognostic 
for poor survival [6,26–33]. A major gap in our understanding remains the identification of the 
neutrophil specific activities that mediate tumor formation and growth.  
Neutrophils contain numerous substances used to defend against pathogens and to mediate wound 
healing in tissue [34,35]. Some of the neutrophil cytoplasmic granule components have been proposed 
to contribute to tumor proliferation, angiogenesis and metastasis [28,29]. One of these is 
myeloperoxidase (MPO), a heme peroxidase enzyme that neutrophils express and secrete, that 
generates reactive oxygen/nitrogen species (ROS/RNS) as a mechanism for pathogen removal. Upon 
neutrophil activation, primary granules containing MPO can fuse with the plasma membrane to secrete 
contents into the extracellular milieu. During the respiratory burst MPO utilizes H2O2 to produce 
hypochlorous acid (HClO) that reacts with proteins, unsaturated fatty acids and any oxidizable group, 
to induce protein adducts and genetic mutations, and influence signaling pathways [36–44]. It has been 




suggested that extended exposure to ROS due to chronic inflammation results in DNA damage and 
genomic instability leading to malignant cell transformation [45,46]. A study in lung epithelial cells 
demonstrated that MPO can be internalized by the cells resulting in increased DNA damage [47]. 
Interestingly, prior studies have indicated that a single nucleotide polymorphism in the human MPO 
gene promoter region is associated with reduced MPO levels and lower risk for developing lung  
cancer [48]. Furthermore, patients suffering from COPD and lung cancer exhibit increased levels of 
MPO in serum and BALF [49,50]. Therefore, we hypothesized that MPO is a target for prevention of 
lung cancer and investigated its role in animal models of lung tumor development. 
In our study, we observed increased levels of MPO in the lungs of BHT-treated mice, consistent 
with that observed in COPD and lung cancer patients [50]. We demonstrate that treatment with KYC,  
a novel tripeptide MPO inhibitor, reduced BHT-promotion of MCA-induced lung carcinogenesis by 
50%. To our knowledge this study is the first demonstration for use of an MPO inhibitor in a mouse 
model of lung cancer. Interestingly, this MPO inhibitor had no effect in a tumor graft model in mouse, 
however the growth of the tumor graft was slowed in an MPO-knockout mouse, suggesting possible 
activity-independent effects of MPO on established tumor growth. That said, our studies suggest that 
use of MPO inhibitors in early in tumor development is a potential new strategy for lung cancer prevention. 
2. Results and Discussion 
2.1. BHT Administration Enhanced Neutrophil and Myeloperoxidase Levels in the Lung 
Our previous studies demonstrated a key role for neutrophils in inflammation-promoted lung 
tumorigenesis [19]. We therefore wanted to determine the neutrophil-related activities that mediate this 
effect. Consistent with previous studies we observed an increase in neutrophil numbers and the 
neutrophil chemoattractant, keratinocyte-derived cytokine (KC)/chemokine (C-X-C motif) ligand 1 
(Cxcl1), in bronchoalveolar lavage fluid (BALF) from female BALB/cByJ (BALB) mice three days 
after treatment with BHT (Figure 1A,B). Protein exudates were similarly increased as measured in the 
BALF with BHT treatment, which is a hallmark of the inflammatory response (Figure 1C). Having 
demonstrated an increase in neutrophils in the BALF after BHT administration, we wanted to 
determine whether myeloperoxidase, a previously reported and highly expressed protumorigenic 
primary granule protein, was elevated in BALF post-BHT. We determined that there was a significant 
6-fold increase in MPO activity after BHT administration (Figure 1D). This observation suggests that 
increased MPO activity is associated with lung inflammation in our tumor model, and justifies 
investigation of the use of MPO inhibitors in preventing tumor promotion.  
2.2. KYC Inhibited BHT-Induced MPO Activity, but not Infiltration of Neutrophils and Levels of MPO 
Enzyme in the Lung 
KYC is a unique tripeptide inhibitor of myeloperoxidase and a potential in vivo preventive  
agent [51,52]. We subsequently tested whether KYC inhibited BHT-induced peroxidase activity in 
BALF. BALB mice were administered KYC (0.3mg/kg/d, subcutaneous) prior to administration of 
BHT. BALF was collected, and peroxidase activity was determined in the cell-free fraction.  




Figure 1. BHT-induced lung inflammation increases lung levels of neutrophils and 
peroxidase activity. Balb/cByJ mice were treated with 300 mg/kg BHT i.p. and euthanized 
three days post injection. (A) BALF was collected, stained for neutrophils (Ly6G+ Gr1+) 
and analyzed by flow cytometry. BHT caused an increase in the number of neutrophils 
collected in the BALF; (B) Neutrophil chemokine CXCL1/KC levels increased in mice 
treated with BHT; (C) BALF supernatant demonstrated increased protein levels in mice 
treated with BHT; (D) BHT enhanced BALF peroxidase activity in mice treated with BHT. 
NS, not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
 
Peroxidase activity in BALF was significantly inhibited in the KYC treatment group (Figure 2A). 
KYC treatment did not affect BHT-induced MPO protein levels in BALF as determined by ELISA 
(Figure 2B). KYC is a reversible inhibitor of MPO and does not irreversibly damage the enzyme as 
compared to other suicide substrate inhibitors [51,52]. Whole BALF was stained for neutrophils using 
specific markers of Ly6G and Gr1. Correspondingly, BHT-induced stimulation of neutrophil numbers 
in the BALF was unaffected by KYC treatment (Figure 2C).  
2.3. KYC Inhibited BHT-Promoted Lung Carcinogenesis 
We next tested the ability of KYC to block inflammation-promoted lung tumorigenesis in the 
MCA/BHT mouse model. Previous studies from our lab demonstrated that antibody-mediated 
depletion of neutrophils reduced lung tumor burden in the MCA/BHT model by 70% [19]. We 
therefore administered KYC (0.3 mg/kg/d, subcutaneous) to BALB strain mice beginning 4 days  
post-MCA treatment, and ending 1 week after the final BHT injection.  












Figure 2. The MPO inhibitor N-acetyl lysyltyrosylcysteine amide (KYC) inhibits lung 
peroxidase activity and not neutrophil lung infiltration. (A) Mice were treated with  
0.3 mg/kg of KYC via subcutaneous injection for one week prior to BHT administration 
(300 mg/kg) and treatment continued for 3 days until mice were euthanized. BALF was 
collected and BHT-stimulated peroxidase activity was reduced by KYC; (B) KYC did not 
affect BHT-induced levels of MPO protein in the BALF; (C) KYC treatment similarly did 
not reduce BHT-stimulated neutrophil levels (left panel). Representative flow cytometry 
plots are shown (right panel). 
 
The average number of surface lung tumors was promoted from 1.0 ± 0.4 to 5.3 ± 1.0 tumors/mouse 
by BHT (p < 0.001), which is consistent with our prior studies [19]. Administration of KYC reduced 
surface lung tumor multiplicity by 50% in BHT treated mice from 5.3 ± 1.0 to 3.1 ± 1.4 tumors/mouse 
(p < 0.05) (Figure 3A). Average tumor diameter was not significantly reduced by KYC treatment 
(Figure 3B), which is consistent with our prior neutrophil-depletion studies [19]. This demonstrates 
that KYC treatment shortly after tumor initiation and throughout inflammation-mediated tumor 
promotion is sufficient to block tumor multiplicity at 20 weeks. 
2.4. KYC Did Not Inhibit Tumor Growth in a Heterotopic Syngeneic Graft Model of Lung Cancer 
We next sought to understand the role of MPO in the in vivo growth of a heterotopic xenografted 
lung cancer cell line in mouse. Wild type female C57BL/6J (B6) or homozygous MPO knockout mice 
(MPO–/–) were given a subcutaneous injection of one million Lewis Lung Carcinoma (LLC) cells in 














1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0





























































































Figure 3. KYC reduces tumor multiplicity in an inflammation-promoted model of  
lung carcinogenesis. (A) BHT induced a 5-fold increase in lung tumor multiplicity  
(MCA: 1.0 ± 0.4; MCA/BHT: 5.3 ± 1.0). Lung tumor multiplicity was reduced by 50% in 
mice treated with KYC (3.1 ± 1.4); (B) Tumor size (i.e., diameter) was unchanged between 
treatment groups. 
 
At the same time, separate groups of wild type mice were treated with or without KYC (sub-cu, 
daily, 3.0 mg/kg) for the duration of the experiment. The size of the tumor graft was evaluated with 
Vernier calipers and volume calculated accordingly. MPO–/– mice had significantly reduced tumor 
volume (p < 0.05) than mice in the control group, while those treated with KYC were indistinguishable 
from the control group (Figure 4A). Tumors were excised and weighed on day 17, and the tumor 
weight for MPO–/– mice was 3 times less than control mice (p < 0.01) (Figure 4B). However, tumors 
from mice treated with KYC at the dose given were indistinguishable in size from the control group 
(Figure 4B). H&E staining indicated increased areas of necrosis in tumors engrafted in MPO–/– mice 
(Figure 4C) in comparison to wild type mice or those treated with KYC. These necrotic areas also 
stained strongly for Ly6G, MPO and cleaved caspase-3. A higher magnification analysis of  
non-necrotic tissue sections indicated increased number of tumor infiltrating neutrophils (Ly6G+), with 
no obvious changes in tumor cell proliferation (Ki-67+) (Figure 4D,E). 
2.5. Discussion 
We have previously observed that BHT administration induced neutrophil infiltration in the airways 
of mice, and that neutrophils were required for BHT-induced promotion of lung carcinogenesis [19]. 
Lung neutrophil infiltration is consistent with observations using other mouse lung tumor promoters 
including lipopolysaccharide (LPS) and non-typeable Haemophilus influenza lysate (NTHil), which 
are often used to model COPD [53–55]. We have now established that BHT induces an increase in 
extracellular MPO in the BALF of mice and inhibition of MPO activity reduces inflammatory 
promotion of lung carcinogenesis. This is consistent with recent data where MPO protein levels were 









Figure 4. Genetic deletion of MPO slows tumor growth in a heterotopic syngeneic tumor 
model. WT and MPO–/– C57BL/6J mice were injected in the right flank with Lewis Lung 
Carcinoma cells. (A) Tumor volume was monitored over the course of 17 days. MPO–/– 
mice exhibited smaller tumors compared to WT. Wild type mice treated with KYC were no 
different than PBS treatment; (B) Tumors were surgically resected and weighed on day 17. 
The weight of tumors from MPO–/– mice was significantly smaller compared to WT mice; 
(C) Representative images of tumors stained for Ly6G, MPO and apoptosis marker cleaved 
caspase-3 (4×); (D) Representative images of non-necrotic sections were immunostained 
for the neutrophil marker Ly6G, MPO, cleaved caspase-3 and proliferation marker Ki-67 
(40×); (E) Tumor infiltrating neutrophils were elevated in MPO–/– mice compared to WT 
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Figure 4. Cont.  
 
Our study is the first to report that inhibition of MPO activity with a non-toxic biologic tripeptide, 
inhibited tumor burden. KYC is novel and a recently described MPO activity inhibitor [51,52]. The 
tyrosine is a natural substrate of MPO and serves as a scavenger for activated MPO preventing its 
ability to convert H2O2 to HOCl. The adjacent cysteine scavenges these tyrosyl radicals, reacts with 
glutathione in vivo and regenerates KYC. Studies have shown that KYC: (a) inhibits MPO-mediated 
oxidant production in vitro and in vivo, (b) is non-toxic in mice, and (c) daily administration to mice 
increases vascular function [51,52].  
KYC reduced MCA-initiated BHT-promoted lung tumor multiplicity by 50% in BALB mice, 
without affecting tumor diameter. Interestingly, KYC at a 10-fold higher dose (3 mg/kg/d) had no 
effect on the growth of LLC tumor cells engrafted on the flank of B6 mice. In contrast, mice 
genetically deficient in MPO had significantly smaller tumors, as measured by weight and volume. 
This may be explained by either: (i) limited bioavailability of KYC in the LLC tumor graft resulting in 
limited MPO activity inhibition, as compared to the complete ablation of MPO activity in the MPO–/– 
mice; or (ii) that MPO activity only plays a role in the early phases of cancer cell growth such as 
initiation/promotion, which are not modeled in the LLC tumor cell graft system. This might suggest 
that MPO protein (independent of activity) could be sufficient for subsequent tumor growth and 
survival. While others have observed reduced asbestos-induced lung epithelial cell proliferation in 












MPO-deficient mice [56], the engrafted tumors do not appear to proliferate less in the knockout. We 
however did observe significant necrosis in tumors in knockout mice, and this was co-incident with 
strong staining for neutrophils, MPO and the apoptosis marker, cleaved caspase-3. This is particularly 
noteworthy as a previous study in ovarian cancer cells lines demonstrated that tumor cell generated 
MPO, in conjunction with iNOS, induced S-nitrosylation of caspase-3, thus protecting cells from 
apoptosis [42]. NO+ generated by MPO can nitrosylate and inactivate caspase-3, via nitrosylation of 
thiol groups (S-nitrosylation), ultimately protecting transformed cells against apoptosis. Although LLC 
cells do not express MPO, this mechanism of MPO-mediated inhibition of caspase-3 activity could 
plausibly operate because MPO can enter lung epithelial cells [47]. In non-necrotic regions of the 
tumor, proliferation (Ki-67 staining) was not affected. Immunohistochemical staining in these regions 
also showed that MPO knockout mice exhibited increased neutrophil numbers in the tumor compared 
to WT mice. This may suggest that under normal conditions, MPO activity suppresses neutrophil 
tumor infiltration, or that a non-enzymatic function of MPO is required for tumor growth post-initiation. 
Previous studies have indicated that enzymatically inactive MPO can play a critical role in modulating 
immune responses including release of pro-inflammatory cytokines, aiding in leukocyte extravasation 
and enhancing neutrophil survival [57–60]. Thus, activity-independent functions of MPO post-initiation 
may play a pivotal role in shaping the immune response to alter tumor growth.  
MPO may also play a larger role in processes occurring immediately after tumor initiation by 
carcinogen. Direct activation of polycyclic aromatic hydrocarbons into DNA damaging metabolites by 
MPO has been documented [61]. Although we did not measure the effects of BHT and KYC treatment 
on MCA-DNA adduct formation, this could be a focus of future investigation. A previous study 
demonstrated that after six weeks of BHT administration, the composition of lung immune cell 
infiltrates is changed to high lymphocyte and macrophage populations, but few neutrophils [15,62]. 
Therefore, it is conceivable that the pro-tumor effects of neutrophil MPO may occur in the window 
immediately post tumor initiation.  
Various models of inflammation-promoted tumorigenesis have demonstrated that neutrophils play a 
key aspect in the progression of cancer. A recent study in a oncogenic K-Ras murine model of  
NTHil-promoted lung cancer demonstrated that either depleting neutrophils or blocking neutrophil 
migration via the KC/Cxcl1 receptor, Cxcr2, reduced tumor burden [63]. Our study builds upon these 
observations and demonstrates that MPO is an important mediator of inflammatory-promoted 
tumorigenesis in the lung. Recent studies have also established that another primary granule enzyme, 
neutrophil elastase (NE), is critical for lung cancer cell growth [63,64]. Neutrophils secrete low levels 
of NE that enter lung epithelial cells and affect proliferative and survival signaling pathways. 
Interestingly, MPO can also enter lung epithelial cells [47,65]. The influence of MPO on the pro-tumor 
functions of NE, or the synergism between the two enzymes has not been investigated. 
KYC may prove to be a promising preventive agent in individuals who suffer from chronic 
inflammation linked to high risk of lung cancer. Our data strongly supports the pursuit of MPO 
inhibitors as potential chemopreventive agents, and evaluation in other lung cancer prevention models 
should be considered. In a guinea pig model of smoking induced COPD, administration of a small 
molecule 2-thioxanthine MPO inhibitor prevented development and progression of emphysema and 
small airway remodeling [66].  




While MPO is involved in innate defense against pathogens, administration to humans in a 
preventive atmosphere is unlikely to be immunosuppressive. An estimated 0.1% of the population has 
some degree of MPO deficiency, is asymptomatic and exhibits no susceptibility to severe or persistent 
infection [67,68]. This suggests that neutrophils have multiple redundant defense mechanisms and 
MPO inhibitors would not inevitably compromise immunity. Other MPO inhibitors, such as azides, 
hydrazides, and hydroxamic acids covalently bind the MPO heme site and act as suicide substrates for 
the enzyme. These inhibitors are not as beneficial as KYC, because they have off-target effects and are 
toxic, thus reducing their probability of being used in a chemopreventive setting [39]. KYC is a 
promising preventive agent with a unique mechanism of action and relatively favorable toxicity  
profile [51,52]. 
3. Experimental  
3.1. BHT Treatment and BALF Collection  
Inbred female BALB/cByJ (BALB) mice were acquired from the Jackson Laboratory (Bar Harbor, 
ME, USA). For lung inflammation assays, mice (at 7 weeks of age) were injected i.p. with 300 mg/kg 
body weight of BHT dissolved in 0.2 mL Mazola corn oil. Corn oil alone was used as a vehicle control. 
Three days after the final injection, bronchoalveolar lavage fluid (BALF) was collected as previously 
described [19]. Cells were collected by centrifugation (10 min @ 200g) and supernatant was used for 
determination of myeloperoxidase protein and activity. KYC, N-acetyl lysyltyrosylcysteine amide, was 
synthesized by Biomatik (Cambridge, ON, Canada) using solid phase technique with Fmoc  
[N-(9-fluorenyl) methoxycarbonyl] chemistry and purified with HPLC to 98% purity. All animal 
procedures were approved by The Medical College of Wisconsin Animal Care and Use Committee. 
3.2. Flow Cytometry Analysis 
Cells isolated from BAL were prepared for flow cytometry as previously described [19,69]. All 
antibodies (Gr-1 (RB6-8C5), Ly6G (1A8) and isotype control antibodies) were acquired from BD 
Pharmingen (San Diego, CA, USA) or eBioscience (San Diego, CA, USA) conjugated to either 
fluorescein isothiocyanate (FITC) or allophycocyanin (APC). Flow cytometry was performed using a 
BD LSRII flow cytometer at the Flow Cytometry Core at the Blood Research Institute (Milwaukee, 
WI, USA). 
3.3. CXCL1/KC ELISA  
CXCL1/KC levels in the BALF were determined using a mouse CXCL1/KC sandwich ELISA from 
R&D Systems (Minneapolis, MN, USA). ELISA was performed per manufacturer’s directions. 
Briefly, 50 µL of samples or standard amounts of recombinant KC were added to each well and 
incubated at room temperature for two hours. After five washes, 100 µL of a polyclonal KC antibody 
conjugated to horshradish peroxidase was added to each well and incubated for two hours at room 
temperature. After another five washes, a 100 µL of the substrate solution, hydrogen peroxide and 
tetramethylbenzidine, was added and incubated in the dark for 30 min. A 100 µL stop solution, diluted 




hydrochloric acid, was added and read at 450 nm with a correction wavelength at 540 nm on the Tecan 
Infinate M200 Pro plate reader. 
3.4. MPO ELISA and Activity Analysis  
MPO protein levels in the cell-free fraction of the BALF were determined using a mouse MPO 
sandwich ELISA by Hycult Biotech (Uden, The Netherlands). ELISA was performed per the 
manufacturer’s directions. Activity of MPO in BALF was determined by the reduction of o-dianisidine. 
Assay buffer consisted of 25 mM phosphate buffer pH 6.5, 0.5 mM o-dianisidine dihydrochloride 
(Sigma Aldrich, St. Louis, MO, USA) and 100 µM H2O2 (Sigma Aldrich). 20 µL of BALF sample was 
mixed with 200 µL assay buffer and read at 460 nm on a Tecan Infinite M200 Pro plate reader (Tecan 
Systems, San Jose, CA, USA) for ten minutes as previously described [70,71].  
3.5. Two Step MCA/BHT Carcinogenesis Assays  
A single i.p. injection of MCA (25 mg/kg body weight in corn oil) was followed by 6 weekly i.p. 
injections of BHT (1st injection: 150 mg/kg, 2nd–6th injections: 200 mg/kg). KYC (0.3 mg/kg) 
peptide dissolved in PBS, was given sub.cu daily beginning 4 days post MCA, and ending 1 week after 
the final BHT injection. At endpoint (20 weeks after MCA injection), mice were anesthetized and 
euthanized. The thoracic cavity was opened, trachea cannulated, and lungs inflation fixed and excised 
as previously described [19]. Lobes were separated and surface lung tumor number/multiplicity, 
diameter (min. 0.25 mm measured by vernier calipers) were blindly assessed under a microscope.  
3.6. Lewis Lung Carcinoma Cell Heterotopic Syngeneic Graft Model  
1 × 106 Lewis Lung Carcinoma (LLC) cells in 0.2 mL of media (DMEM +10% FBS) were injected 
into the right flank of female (7 weeks, n = 6 per group) C57BL/6J and C57BL/6J-MPO–/– deficient 
mice (Jackson Labs #4265). WT mice were treated daily with 3 mg/kg KYC (subcutaneous) or with 
PBS controls beginning on day 1 until endpoint. Tumor volume (V = (length × width2)/2) was 
monitored via caliper measurements over 17 days and on the final day excised tumors were weighed. 
3.7. Immunohistochemical Staining 
Tissues were fixed for 24 h in zinc formalin then placed in 70% ethanol. Tissue samples were 
processed in paraffin by the Children’s Research Institute Histology Core. Antigen retrieval was done 
in citrate buffer at pH 6.0 for 20 min. Sections were stained using a DAKO Autostainer Plus (DAKO 
North America, Carpinteria, CA, USA) at dilutions of 1:200 for anti-Ly6G (NIMP-R14, Santa Cruz 
Biotechnology, Dallas, TX, USA), 1:150 for anti-MPO (ab9535, Abcam, Cambridge, MA, USA), 
1:100 for cleaved caspase-3 (CP229B, Biocare Medical, Concord, CA, USA), 1:200 for Ki-67 (D3B5, 
Cell Signaling Technology, Danvers, MA, USA) and for H&E. Slides were imaged on a Nikon Eclipse 
50i microscope (Nikon Instruments, Melville, NY, USA) and analyzed using NIS Elements BR 
software (Nikon). Quantification was done by selecting cells that stained positive for the antibody of 
interest, selecting a threshold, which was then applied to all images in that set. The percent area was 




calculated by determining the area that stained positive for the antigen and dividing it by the total area 
of the image.  
3.8. Western Blot Analysis 
Tumors were excised and frozen at –80 °C until needed. Tumor tissue was mechanically 
homogenized in RIPA lysis buffer consisting 1 mM 2-mercaptoethanol, phosphatase inhibitor cocktails 
II and III (Sigma Aldrich), and Sigmafast protease inhibitors (Sigma Aldrich). Samples were 
centrifuged at high speed and the supernatant protein concentration was determined using Peirce BSA 
Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 10 µg of protein was loaded into a 4%–15% 
mini-Protean TGX polyacrylamide gel (Bio-Rad, Hercules, CA, USA) and electrophoresed at 180 
volts. Protein was then transferred to PVDF at 100 volts for an hour and then blocked for 30 min in 1% 
milk in TBST buffer. Primary antibody (1:3000 dilution for cleaved caspase-3 (Cell Signaling, 5A1E) 
and 1:15,000 for actin (A2066, Sigma Aldrich) was incubated with the membrane overnight. The next 
day, secondary HRP-conjugated antibody was added for 1 hour, and blots were developed using 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Rockford, IL, USA) and 
exposed to film. 
3.9. Statistical Analysis  
All analysis of significance (p < 0.05) was performed by two-tailed Student’s t-Test. Wilcoxon test 
was performed for MCA/BHT/KYC tumor study.  
4. Conclusions 
In this study, we demonstrated that inhibition of MPO activity by a novel tripeptide inhibitor KYC 
in the MCA-initiated BHT-promoted model of lung carcinogenesis, reduced tumor burden by 50%. 
Interestingly, treatment with KYC in an LLC tumor graft model exhibited no effect on tumor size, yet 
tumor size was significantly reduced in MPO–/– mice. We postulate that MPO activity is required 
during the early phases of tumor initiation and promotion, while non-enzymatic functions of MPO play 
a role during later phases of tumor progression through protection of cancer cells against  
caspase-3 mediated cell death. Patients at increased risk of lung cancer, such as those with COPD, may 
benefit from prophylactic treatment with non-toxic MPO inhibitors to reduce chances of developing 
lung cancer.  
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